Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide
Laurie-Anne Roeckel, Valérie Utard, David Reiss, Jinane Mouheiche, Hervé Maurin, Anne Robé, Emilie Audouard, John N Wood, Yannick Goumon, Frédéric Simonin, Claire Gaveriaux-Ruff, Laurie-Anne Roeckel, Valérie Utard, David Reiss, Jinane Mouheiche, Hervé Maurin, Anne Robé, Emilie Audouard, John N Wood, Yannick Goumon, Frédéric Simonin, Claire Gaveriaux-Ruff
Abstract
Opiates are potent analgesics but their clinical use is limited by side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH). The Opiates produce analgesia and other adverse effects through activation of the mu opioid receptor (MOR) encoded by the Oprm1 gene. However, MOR and morphine metabolism involvement in OIH have been little explored. Hence, we examined MOR contribution to OIH by comparing morphine-induced hyperalgesia in wild type (WT) and MOR knockout (KO) mice. We found that repeated morphine administration led to analgesic tolerance and hyperalgesia in WT mice but not in MOR KO mice. The absence of OIH in MOR KO mice was found in both sexes, in two KO global mutant lines, and for mechanical, heat and cold pain modalities. In addition, the morphine metabolite morphine-3beta-D-glucuronide (M3G) elicited hyperalgesia in WT but not in MOR KO animals, as well as in both MOR flox and MOR-Nav1.8 sensory neuron conditional KO mice. M3G displayed significant binding to MOR and G-protein activation when using membranes from MOR-transfected cells or WT mice but not from MOR KO mice. Collectively our results show that MOR is involved in hyperalgesia induced by chronic morphine and its metabolite M3G.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
- Wolkerstorfer A, Handler N, Buschmann H. New approaches to treating pain. Bioorg Med Chem Lett. 2016;26:1103–1119. doi: 10.1016/j.bmcl.2015.12.103.
- Gaveriaux-Ruff C. Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants. Curr Pharm Des. 2013;19:7373–7381. doi: 10.2174/138161281942140105163727.
- Trang T, et al. Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics. J Neurosci. 2015;35:13879–13888. doi: 10.1523/JNEUROSCI.2711-15.2015.
- Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience. 2016;338:160–182. doi: 10.1016/j.neuroscience.2016.06.029.
- Rivat C, Ballantyne J. The dark side of opioids in pain management: basic science explains clinical observation. Pain reports. 2016;1 doi: 10.1097/PR9.0000000000000570.
- Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs. 2015;29:465–486. doi: 10.1007/s40263-015-0255-x.
- Hutchinson MR, et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63:772–810. doi: 10.1124/pr.110.004135.
- Lewis SS, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience. 2010;165:569–583. doi: 10.1016/j.neuroscience.2009.10.011.
- Due MR, et al. Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling. J Neuroinflammation. 2012;9 doi: 10.1186/1742-2094-9-200.
- Bai L, et al. Toll-like receptor 4-mediated nuclear factor-kappaB activation in spinal cord contributes to chronic morphine-induced analgesic tolerance and hyperalgesia in rats. Neurosci Bull. 2014;30:936–948. doi: 10.1007/s12264-014-1483-7.
- Johnson JL, et al. Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. Transl Psychiatry. 2014;4 doi: 10.1038/tp.2014.121.
- Ellis A, et al. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav Immun. 2016;58:348–356. doi: 10.1016/j.bbi.2016.08.004.
- Ferrini F, et al. Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl(-) homeostasis. Nat Neurosci. 2013;16:183–192. doi: 10.1038/nn.3295.
- Mattioli TA, et al. Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence. PLoS One. 2014;9 doi: 10.1371/journal.pone.0097361.
- Skolnick P, Davis H, Arnelle D, Deaver D. Translational potential of naloxone and naltrexone as TLR4 antagonists. Trends Pharmacol Sci. 2014;35:431–432. doi: 10.1016/j.tips.2014.06.008.
- Mogil JS. Perspective: Equality need not be painful. Nature. 2016;535 doi: 10.1038/535S7a.
- Melchior M, Poisbeau P, Gaumond I, Marchand S. Insights into the mechanisms and the emergence of sex-differences in pain. Neuroscience. 2016;338:63–80. doi: 10.1016/j.neuroscience.2016.05.007.
- Doyle HH, Murphy AZ. Sex differences in innate immunity and its impact on opioid pharmacology. J Neurosci Res. 2017;95:487–499. doi: 10.1002/jnr.23852.
- Rosen S, Ham B, Mogil JS. Sex differences in neuroimmunity and pain. J Neurosci Res. 2017;95:500–508. doi: 10.1002/jnr.23831.
- Matthes HW, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383:819–823. doi: 10.1038/383819a0.
- Weibel R, et al. Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. PLoS One. 2013;8 doi: 10.1371/journal.pone.0074706.
- Fukagawa H, Koyama T, Kakuyama M, Fukuda K. Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4. J Anesth. 2013;27:93–97. doi: 10.1007/s00540-012-1469-4.
- Corder G, et al. Constitutive mu-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science. 2013;341:1394–1399. doi: 10.1126/science.1239403.
- Khabbazi S, Xie N, Pu W, Goumon Y, Parat MO. The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro. Front Pharmacol. 2016;7 doi: 10.3389/fphar.2016.00441.
- Frolich N, et al. Distinct pharmacological properties of morphine metabolites at G(i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor. Biochem Pharmacol. 2011;81:1248–1254. doi: 10.1016/j.bcp.2011.03.001.
- Corder G, et al. Loss of mu opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. Nat Med. 2017;23:164–173. doi: 10.1038/nm.4262.
- Law PY, Reggio PH, Loh HH. Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci. 2013;38:275–282. doi: 10.1016/j.tibs.2013.03.003.
- Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65:1257–1317. doi: 10.1124/pr.112.007138.
- Convertino M, et al. mu-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids. Prog Neuropsychopharmacol Biol Psychiatry. 2015;62:61–67. doi: 10.1016/j.pnpbp.2014.11.009.
- Gris P, et al. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain. 2010;6 doi: 10.1186/1744-8069-6-33.
- Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA. 1995;92:10540–10544. doi: 10.1073/pnas.92.23.10540.
- Crain SM, Shen KF. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res. 2004;995:260–266. doi: 10.1016/j.brainres.2003.09.068.
- Oladosu FA, et al. Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia. PLoS One. 2015;10 doi: 10.1371/journal.pone.0135711.
- Machelska H, Celik MO. Recent advances in understanding neuropathic pain: glia, sex differences, and epigenetics. F1000Res. 2016;5 doi: 10.12688/f1000research.9621.1.
- Sorge RE, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci. 2015;18:1081–1083. doi: 10.1038/nn.4053.
- Taves S, et al. Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain Behav Immun. 2016;55:70–81. doi: 10.1016/j.bbi.2015.10.006.
- Holtman JR, Jr., Wala EP. Characterization of morphine-induced hyperalgesia in male and female rats. Pain. 2005;114:62–70. doi: 10.1016/j.pain.2004.11.014.
- Arout CA, Caldwell M, Rossi G, Kest B. Spinal and supraspinal N-methyl-D-aspartate and melanocortin-1 receptors contribute to a qualitative sex difference in morphine-induced hyperalgesia. Physiol Behav. 2015;147:364–372. doi: 10.1016/j.physbeh.2015.05.006.
- Juni A, Klein G, Kowalczyk B, Ragnauth A, Kest B. Sex differences in hyperalgesia during morphine infusion: effect of gonadectomy and estrogen treatment. Neuropharmacology. 2008;54:1264–1270. doi: 10.1016/j.neuropharm.2008.04.004.
- Juni A, et al. Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology. 2010;112:181–188. doi: 10.1097/ALN.0b013e3181c53849.
- Melik Parsadaniantz S, Rivat C, Rostene W, Reaux-Le Goazigo A. Opioid and chemokine receptor crosstalk: a promising target for pain therapy? Nat Rev Neurosci. 2015;16:69–78. doi: 10.1038/nrn3858.
- Thomas J, Mustafa S, Johnson J, Nicotra L, Hutchinson M. The relationship between opioids and immune signalling in the spinal cord. Handb Exp Pharmacol. 2015;227:207–238. doi: 10.1007/978-3-662-46450-2_11.
- Rubovitch V, Pick CG, Sarne Y. Is withdrawal hyperalgesia in morphine-dependent mice a direct effect of a low concentration of the residual drug? Addict Biol. 2009;14:438–446. doi: 10.1111/j.1369-1600.2009.00164.x.
- Handal M, Grung M, Skurtveit S, Ripel A, Morland J. Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Pharmacol Biochem Behav. 2002;73:883–892. doi: 10.1016/S0091-3057(02)00925-5.
- Drewe J, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol. 2000;50:237–246. doi: 10.1046/j.1365-2125.2000.00226.x.
- Mignat C, Jansen R, Ziegler A. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine. J Pharm Pharmacol. 1995;47:171–175. doi: 10.1111/j.2042-7158.1995.tb05772.x.
- Juni A, Klein G, Kest B. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. Brain Res. 2006;1070:35–44. doi: 10.1016/j.brainres.2005.11.054.
- Mignat C, Wille U, Ziegler A. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56:793–799. doi: 10.1016/0024-3205(95)00010-4.
- Thompson GL, Kelly E, Christopoulos A, Canals M. Novel GPCR paradigms at the mu-opioid receptor. Br J Pharmacol. 2015;172:287–296. doi: 10.1111/bph.12600.
- Yang Z, et al. Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid via Down-Regulating UGT2B7. Front Pharmacol. 2016;7
- Su W, Pasternak GW. The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia. Synapse. 2013;67:609–619. doi: 10.1002/syn.21667.
- Yang ZZ, et al. siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression. Sci Rep. 2016;6 doi: 10.1038/srep33338.
- Khabbazi S, Goumon Y, Parat MO. Morphine Modulates Interleukin-4- or Breast Cancer Cell-induced Pro-metastatic Activation of Macrophages. Sci Rep. 2015;5 doi: 10.1038/srep11389.
- Wan J, Ma J, Anand V, Ramakrishnan S, Roy S. Morphine potentiates LPS-induced autophagy initiation but inhibits autophagosomal maturation through distinct TLR4-dependent and independent pathways. Acta Physiol (Oxf) 2015;214:189–199. doi: 10.1111/apha.12506.
- Xie N, et al. Activation of mu-opioid receptor and Toll-like receptor 4 by plasma from morphine-treated mice. Brain Behav Immun. 2017;61:244–258. doi: 10.1016/j.bbi.2016.12.002.
- Gessi S, et al. The activation of mu-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia. FEBS Lett. 2016;590:2813–2826. doi: 10.1002/1873-3468.12313.
- Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312–1326. doi: 10.1016/j.cell.2014.11.018.
- Denk F, Crow M, Didangelos A, Lopes DM, McMahon SB. Persistent Alterations in Microglial Enhancers in a Model of Chronic Pain. Cell Rep. 2016;15:1771–1781. doi: 10.1016/j.celrep.2016.04.063.
- Lagerstrom MC, et al. VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Neuron. 2010;68:529–542. doi: 10.1016/j.neuron.2010.09.016.
- Usoskin D, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18:145–153. doi: 10.1038/nn.3881.
- Vanderah TW, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21:279–286.
- Cahill CM, Walwyn W, Taylor AM, Pradhan AA, Evans CJ. Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation. Trends Pharmacol Sci. 2016;37:963–976. doi: 10.1016/j.tips.2016.08.002.
- Gerhold KJ, Drdla-Schutting R, Honsek SD, Forsthuber L, Sandkuhler J. Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude. J Neurosci. 2015;35:9580–9594. doi: 10.1523/JNEUROSCI.0731-14.2015.
- Bobeck EN, Ingram SL, Hermes SM, Aicher SA, Morgan MM. Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance. Behav Brain Res. 2016;298:17–24. doi: 10.1016/j.bbr.2015.10.032.
- Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537:185–190. doi: 10.1038/nature19112.
- Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular Pharmacology of delta-Opioid Receptors. Pharmacol Rev. 2016;68:631–700. doi: 10.1124/pr.114.008979.
- Samoshkin A, et al. Structural and functional interactions between six-transmembrane mu-opioid receptors and beta2-adrenoreceptors modulate opioid signaling. Sci Rep. 2015;5 doi: 10.1038/srep18198.
- McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1573–1576. doi: 10.1111/j.1476-5381.2010.00873.x.
- Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain. 1998;76:215–222. doi: 10.1016/S0304-3959(98)00045-1.
- Gaveriaux-Ruff C, et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain. 2011;152:1238–1248. doi: 10.1016/j.pain.2010.12.031.
- Becker JA, et al. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem. 1999;274:27513–27522. doi: 10.1074/jbc.274.39.27513.
- Michel G, et al. Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation. J Cell Sci. 2014;127:773–787. doi: 10.1242/jcs.136432.
- Morse M, Tran E, Sun H, Levenson R, Fang Y. Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One. 2011;6 doi: 10.1371/journal.pone.0025643.
Source: PubMed